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Abstract
Background: The process of DNA replication requires the separation of complementary DNA
strands. In this process, the unwinding of circularly closed or long DNA duplices leads to torsional
tensions which must be released by topoisomerases. So topoisomerases play an important role in
DNA replication. In order to provide more information about topoisomerases in the initiation of
mammalian replication, we investigated whether topoisomerases occur close to ORC in the
chromatin of cultured human HeLa cells.
Results: We have used different cell fractionation procedures, namely salt and nuclease treatment
of isolated nuclei as well as formaldehyde-mediated cross-linking of chromatin, to investigate the
distribution of topoisomerases and proteins of the origin recognition complex (ORC) in the
chromatin of human HeLa cells. First we obtained no evidence for a physical interaction of either
topoisomerase I or topoisomerase II with ORC. Then we found, however, that (Orc1-5) and topo
II occurred together on chromatin fragments of 600 and more bp lengths. At last we showed that
both topo II and Orc2 protein are enriched near the origin at the human MCM4 gene, and at least
some of the topo II at the origin is active in proliferating HeLa cells. So taken together,
topoisomerase II, but not topoisomerase I, is located close to ORC on chromatin.
Conclusion: Topoisomerase II is more highly expressed than ORC proteins in mammalian cells,
so only a small fraction of total chromatin-bound topoisomerase II was found in the vicinity of ORC.
The precise position of topo II relative to ORC may differ among origins.
Background
DNA replication requires the separation of complemen-
tary DNA strands. This process begins at the origin of rep-
lication under the direction of initiator proteins such as
the T antigen of Simian Virus 40 (SV40) or the eukaryotic
preinitiation complex including ORC (origin recognition
complex). The unwinding of circularly closed or long
DNA duplices leads to torsional tensions which must be
released by topoisomerases. According to earlier bio-
chemical work, high local concentrations of the eukaryo-
tic type IB topoisomerase (topo I) and a type II
topoisomerase (topo II) are required to release the tor-
sional stress that accompanies the initiation and propaga-
tion of replication forks on closed circular SV40 viral DNA
in vitro [1-3]. Further, topo I was shown to be mainly
located in vivo at regions ahead of the replication forks on
replicating SV40 DNA molecules, while topo II also occurs
in pre-fork regions, but is essential for the decatenation of
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replicated DNA circles [4-7]. In fact, both eukaryotic topo
I and topo II have the properties to release the positive
supercoils that form ahead of the advancing replication
forks, and the negative supercoils that accumulate in the
replicated DNA sections [8,9].
In yeast cells, topo I seems to normally provide the swivel
for replicative fork movement, but yeast mutants without
topo I are viable because topo II can substitute for topo I
in replication intermediates. However, topo II is abso-
lutely required to decatenate linked chromosomes and to
assist in the segregation of chromosomes at mitosis [8,9].
To provide additional information about topoisomerases
in mammalian replication initiation, we investigated
whether topoisomerases occur close to ORC in the chro-
matin of cultured human HeLa cells. ORC is the six-mem-
bered protein complex that marks the sites on eukaryotic
chromosomes where prereplication complexes assemble,
and where replication initiations occur at the beginning of
S phase in the cell cycle [10,11]. Two major forms of ORC
can be distinguished in asynchronously proliferating
HeLa cells. One form, (Orc1-5), contains proteins Orc1p
to Orc5p and is the predominant form in prereplicative
G1 phase cells. During the S phase, protein Orc1p dissoci-
ates from ORC in HeLa cells leaving behind the second
form of ORC, (Orc2-5). The sixth canonical Orc protein,
Orc6p, appears to be loosely associated with either form
and is usually lost during extractions or immunoprecipi-
tations [12-15].
Mammalian cells express two isoforms of topo II, α and β,
which are similar in their primary structures and enzy-
matic properties, but have different functions in prolifer-
ating cells. Topo IIα relaxes positive supercoils (as occur at
replication forks) much more efficiently than negative
supercoils [16]. Indeed, topo IIβ appears to have no pref-
erence for positive supercoils, and may be involved in the
regulation of transcription rather than replication [17].
Therefore, we focus here on topo IIα (abbreviated below
as topo II).
Recently, Abdurashidova et al. [18] have mapped the sites
of active topo I and topo II at the mammalian lamin B2
origin using specific inhibitors that block the topoisomer-
ase-reaction cycle after DNA strand cleavage. This elegant
study provides evidence that both topo I and topo II are
active at this particular origin at all phases of the cell cycle.
However, the presence of the topoisomerases was deter-
mined indirectly by the footprints they leave in the form
of DNA strand cleavages. The focus of the present study is
different as it determines the presence of topoisomerases
directly by Western blotting. We use different cell fraction-
ation techniques which together show that topo II resides
on chromatin in close neighborhood to ORC, but it
became also clear that is only a small fraction of chroma-
tin-bound topoisomerases, and that the vast majority of
topo I and topo II resides elsewhere on chromatin.
Methods
Cell culture and cell fractionation
Human HeLa S3 cells were grown on plastic dishes in Dul-
becco's modified Eagle's medium plus 5% calf serum.
Nuclei were prepared and processed for salt extraction or
treatment with micrococcal nuclease as described by Kre-
itz et al. [12]. Cross-linking by formaldehyde and the
processing of cross-linked chromatin has been described
in detail by Ladenburger et al. [19].
Antibodies and immunoprecipitations
Antibodies against Orc and Mcm proteins were prepared
in this laboratory and have been described before [12,20].
Monoclonal mouse antibodies against the DNA topoi-
somerases are from Biozol Diagnostica (Eching, Ger-
many). Antibodies were used for immunoprecipitations
and immunoblotting as in [20]. Ladenburger et al. [19]
describe the conditions for chromatin-immunoprecipita-
tion (ChIP) and for quantitative PCR including the prim-
ers used in this communication.
Results
To investigate a possible association of topoisomerases
with ORC, we first treated isolated nuclei from asynchro-
nously proliferating HeLa cells with increasing salt con-
centrations and used the supernatants to perform
immunoblottings for the determination of Orc1p, Orc2p,
topo I and II.
As previously described [12], the (Orc2-5) form of ORC
(see: Introduction) is released from isolated nuclei in
buffers of 0.2 – 0.25 M salt; while the (Orc1-5) form is
more tightly bound to chromatin and requires at least
0.32 M salt to be released from chromatin. We determined
Orc1p as a proxy for (Orc1-5) and Orc2p (in the absence
of Orc1p) for (Orc2-5).
The distribution of Orc2p and Orc1p over the various salt
fractions in the experiment of Fig. 1 conforms to this
description because most of Orc1p occurred in the high
salt supernatant whereas Orc2p appeared in both, the
0.25 M and in the 0.32 M salt wash. In addition to its pres-
ence in the two ORC forms, small amounts of Orc2p were
detected in the cytosol and in the insoluble pellet (Fig. 1)
and may reflect the presence of Orc2p in centrosomes and
heterochromatin, respectively, as recently described [21].
Both, topo I and topo II, were distributed in the fractions
with 0.25 M and 0.32 M NaCl much like Orc1p (Fig. 1).
To determine whether the topoisomerases were in direct
contact with ORC, we performed immunoprecipitationsBMC Molecular Biology 2009, 10:36 http://www.biomedcentral.com/1471-2199/10/36
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using specific antibodies against Orc1p, Orc2p, topo I or
topo II. We were unable to detect coprecipitations of one
or the other of the topoisomerases with either (Orc1-5) or
(Orc2-5) (not shown) which makes it unlikely that the
topoisomerases directly and stably interact with ORC
under the experimental conditions.
This does not exclude the possibility that ORC and a
topoisomerase are located at adjacent sites on the chroma-
tin. To investigate this point, we treated isolated HeLa cell
nuclei, which contain 50 μg DNA, with micrococcal
nuclease (MN; 10 – 100 units/50 μg DNA) [12]. After an
incubation time of 15 min with 10 units MN, 60 – 70% of
the DNA in chromatin were mobilized and appeared in
the supernatant of low speed centrifugation while the rest
was insoluble in the Ca++ – containing buffer needed for
MN digestion. More units of MN (Fig. 2A) or longer incu-
bation times (not shown) did not increase the fraction of
solubilized DNA, but further degraded the DNA in both,
the supernatant and the pellet fraction of chromatin (Fig.
2B). As expected from earlier work [12,15], we detected
Orc2p as a component of (Orc2-5) bound to chromatin
fragments in the MN supernatant whereas Orc1p in
(Orc1-5) remained in the pellet fraction (Fig. 2C). Most of
topo I and essentially all topo II were also in the pellet
(Fig. 2C).
Based on previous experiments [19], we expected the
(Orc1-5) complexes to be located at replication origins.
To verify this prediction, we used quantitative PCR and
found indeed that sequences corresponding to the
mapped UPR origin [19] were 50 fold and sequences of
Orc proteins dissociate together with topoisomerases from chromatin Figure 1
Orc proteins dissociate together with topoisomerases from chromatin. HeLa cell nuclei were prepared and treated 
with nuclear extraction (NE) buffer containing 80, 250, 320 and 450 mM NaCl as indicated. The supernatants were analyzed by 
polyacrylamide gel electrophoresis in the presence of SDS and western blotting.BMC Molecular Biology 2009, 10:36 http://www.biomedcentral.com/1471-2199/10/36
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Orc1p in (Orc1-5) together with a considerable part of topo I and topo II cannot be mobilized by nuclease treatment Figure 2
Orc1p in (Orc1-5) together with a considerable part of topo I and topo II cannot be mobilized by nuclease 
treatment. (A) Isolated nuclei (50 μg DNA) were treated for 15 min with MN in the amounts indicated. DNA concentrations 
were determined in the supernatants (not shown) and the pellet. (B) DNA in supernatants and the pellets were deproteinized 
and analyzed by agarose gel electrophoresis and staining with ethidium bromide. (C) Proteins in the supernatants and the pel-
lets were investigated by western blotting.BMC Molecular Biology 2009, 10:36 http://www.biomedcentral.com/1471-2199/10/36
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the Lamin B2 origin [22] were 80 fold more abundant in
the pellet fraction than origin-free control DNA (the exon
9 (Ex9) sequence in the human MCM4 gene [19]) (data
not shown).
While the data in Fig. 2 showed that the two topoisomer-
ases occurred together with (Orc1-5) in the chromatin
pellet fraction (Fig. 2C), we wished to find out whether a
topoisomerase and ORC colocalized on the same chroma-
tin fragment. For this purpose, we took advantage of the
fact that a considerable part of the chromatin pellet that
remains after MN-treatment can be suspended in a low-
salt, high-EDTA buffer (20 mM EDTA, 10 mM Hepes; pH
7.4) which does not disrupt protein-DNA interactions in
chromatin. The resuspended chromatin fragments were
separated by sucrose gradient centrifugation.
(Orc1-5) was expected to sediment in fractions 4 and 5
(sedimentation coefficient: 11 S) and free topoisomerases
in fractions 2 and 3 (sedimentation coefficient: 3 – 5 S) of
a sucrose gradient like that shown in Fig. 3A (data not
shown). However, Orc1p and Orc2p sedimented faster
and together with dinucleosomal and larger chromatin
fragments. Topo I was distributed over many sucrose gra-
dient fractions with a maximum that coincided with dinu-
cleosomal fragments. In contrast, topo II sedimented
faster and appeared together with Orc1p and Orc2p at
chromatin fragments with three and more nucleosomes
(Fig. 3A). To determine whether ORC and topo II
occurred together on the chromatin fragments, we used
the sucrose gradient fractions 8 and 9 (with trinucleo-
somal chromatin; Fig. 3A) for immunoprecipitations, and
found that the Orc2p-antibodies precipitated, as expected,
essentially all chromatin-bound Orc2p (compare super-
natant and pellet in the immunoprecipitates of Fig. 3B)
together with a small fraction of the immunologically
detectable topo II, in contrast to topo I which could not be
detected in the immunoprecipitates (Fig. 3B). This result
suggests that (Orc1-5) and topo II occurred together on
chromatin fragments of ca. 600 bp length.
However, the data also show that only a rather small frac-
tion of total chromatin-bound topo II is linked to ORC,
while the vast majority of topo II is distributed elsewhere
in the chromatin. This may be the reason why in the
experiment of Fig. 3B no Orc2p could be seen in the
immunoprecipitate obtained with topo II-specific anti-
bodies as these antibodies precipitated only part of the
total chromatin-bound topo II. It seems that much of
chromatin-bound topo II was inaccessible to the antibod-
ies, and this could include the topo II in the vicinity of
(Orc1-5).
We found it necessary to obtain additional evidence for a
linkage of (Orc1-5) and topo II at replication origins.
Therefore, we cross-linked chromatin proteins to DNA by
a treatment of HeLa cells with formaldehyde exactly as
described in [19]. Cross-linked chromatin was treated
with MN producing DNA pieces of average lengths of ca.
500 bp. The chromatin fragments were immunoprecipi-
tated with topo II- and Orc2p-specific antibodies, depro-
teinized and analyzed by quantitative PCR using primers
specific for regions at and around the mapped origins of
the human MCM4 gene (Fig. 4A). We found that both,
topo II- and Orc2p-specific antibodies, enriched origin-
proximal sequences relative to origin-distal sequences
around the MCM4 gene (Fig. 4B). These data support the
notion that ORC and topo II can simultaneously occur in
a DNA region of several hundred bp at the UPR replica-
tion origin.
As additional evidence for the presence of topo II at the
MCM4 origin, we used the topo II- specific drug etoposide
which inhibits the topoisomerase reaction cycle after
DNA strand cleavage [23]. Thus, if topo II is present and
active, the MCM4 origin region should be broken in
etoposide-treated cells and therefore inaccessible to PCR.
We found indeed that etoposide caused a decrease of
amplifiable  MCM4  origin DNA to 60 – 70% of the
untreated control (Fig. 4C) indicating that at least some of
the topo II at the origin is active in proliferating HeLa
cells. As a control, we studied the lamin B2 origin in the
same experiment and interestingly found that it is much
more sensitive because etoposide-treatment reduced the
amplifiable lamin B2 origin DNA to 20% of the control
(Fig. 4C). This is in agreement with Abdurashidova et al.
[18] who determined that topo II is active on the lamin B2
origin during all phases of the cell cycle.
Discussion
We have used three different cell fractionation procedures
to investigate the distribution of DNA topoisomerases rel-
ative to ORC on chromatin of proliferating human HeLa
cells.
In a first procedure, we treated isolated nuclei with
increasing salt distinguishing the prereplicative form of
ORC, (Orc1-5), from its post-initiation form, (Orc2-5).
The former needs higher salt concentrations than the lat-
ter for a dissociation from chromatin. Chromatin-bound
topoisomerases I and II distribute almost equally between
the two fractions, but no evidence for a direct interaction
of one or the other topoisomerase with either ORC form
was obtained through coimmunoprecipitation experi-
ments. Thus, the cellular initiator proteins in ORC differ
from the viral initiator T antigen which appears to physi-
cally interact with topoisomerase [3].BMC Molecular Biology 2009, 10:36 http://www.biomedcentral.com/1471-2199/10/36
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Orc proteins cosediment mainly with topo II Figure 3
Orc proteins cosediment mainly with topo II. (A) The pelleted chromatin in MN-treated nuclei (Fig. 2) was partially sus-
pended in a low salt – high EDTA buffer and investigated by centrifugation through a sucrose gradient (5 – 20%) made up in the 
same buffer. A part of each gradient fraction was deproteinized and analyzed by agarose gel electrophoresis and staining with 
ethidium bromide (upper panel). Another part of each fraction was investigated by western blotting. (B) The combined frac-
tions 8 and 9 in (A) were incubated with either control antibodies (IgG) or antibodies specific for Orc2p or topo II. The precip-
itates were rigorously washed with 80 mM NaCl in NE buffer. The supernatants and the immunoprecipitates were analyzed by 
western blotting.BMC Molecular Biology 2009, 10:36 http://www.biomedcentral.com/1471-2199/10/36
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The second approach was digestion of chromatin with
MN. Again, the pre- and the post-initiation ORC forms
behave differently. The pre-initiation form (Orc1-5) is
rather inaccessible to MN and remains in an unsoluble
nucleoprotein fraction consisting of many components
including architectural proteins and active transcription
complexes [24]. In contrast, the post-initiation form
(Orc2-5) is mobilized by MN just as the majority of chro-
matin. The topoisomerases distribute between the MN-
accessible and the insoluble fraction. Analysis of the pellet
fraction by sucrose gradient centrifugation helped to clar-
ify the situation as most of topo I sedimented in gradient
fractions without ORC whereas topo II cosedimented
with and were probably bound to larger chromatin frag-
ments that also carried ORC. Indeed, immunoprecipita-
tions directly showed that (Orc1-5) and topo II occurred
on the same chromatin fragments of 600 and more bp
lengths.
Our third method to study the binding of ORC and topoi-
somerase to chromatin was formaldehyde-mediated
cross-linking. We have used this technique before in our
studies on the chromatin-binding of ORC and Mcm pro-
teins [19,20]. Here, we show that ORC and topo II (but
not topo I) are located together on chromatin fragments
of ca. 500 bp.
Conclusion
Taken together, the data reveal that only a small fraction
of total chromatin-bound topoisomerases are located in
the neighborhood of ORC, whereas the vast majority is
located elsewhere in the chromatin. In particular, we have
no evidence that topo I occurs close enough to ORC on
chromatin to be coprecipitated with ORC on MN diges-
tion products, or to be cross-linked together with ORC on
chromatin fragments of ca. 500 bp. In this context, we
note a recent publication showing that it is topo II, not
topo I, which is most active relaxing torsional strain on
nucleosomal DNA [25].
Indeed, topo II could be detected in the vicinity of ORC.
Topo II is expressed in a large excess over the ten thousand
or so ORC molecules per HeLa cell nucleus [12], and
therefore the great majority of topo II must be on chroma-
tin sites other than replication origins. However, it is inter-
esting that in our cross-linking experiments topo II was
found to be enriched in the origin/promoter region of the
MCM4 gene (and of the TOP1 gene; not shown) but not
in the transcribed sections. This clearly indicates that topo
II does not randomly distribute on the genome, but pre-
fers specific sites of which replication origins are an exam-
ple. We cannot say yet whether topo II and ORC reside so
closely on chromatin as to touch each other as the work of
Abdurashidova et al. [18] seems to suggest. We like to
argue though that the precise positions of topo II may dif-
fer among origins. This may be the reason why we found
the lamin B2 origin to be more sensitive to the topo II-
poison etoposide than the MCM4 or TOP1 origins. The
position of topoisomerases may depend on other genetic
elements in the vicinity of the origins such as overlapping
enhancer or promoter elements. However, this point
requires additional attention.
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